The enormous technology conglomerate Softbank is continuing its spending spree, this time investing $1.1 billion into biotech firm Roivant Sciences. The drugmaker is currently developing seven neurological therapies and several treatments for rare diseases, among others. It’s the first time that Softbank has dipped into its $93 billion Vision Fund, which includes cash from Saudi Arabia, to support a drugmaker. Roivant’s CEO, Vivek Ramaswamy, tells Endpoints that the funding injection won’t all be used for regular biotech ideas: instead, some of it will be funnelled into what he calls “new technologies that can improve a biotech’s efficiency.”
Softbank is on a huge spending spree right now. In the past year, it has acquired the British chip designer ARM, invested $4 billion into chipmaker Nvidia, turned the London-based simulation startup Improbable into a unicorn, and gobbled up the robot maker Boston Dynamics. Next stop, drug tech.
It will soon be easy for self-driving cars to hide in plain sight. We shouldn’t let them.
If they ever hit our roads for real, other drivers need to know exactly what they are.
Maximize business value with data-driven strategies
Every organization is now collecting data, but few are truly data driven. Here are five ways data can transform your business.
Cryptocurrency fuels new business opportunities
As adoption of digital assets accelerates, companies are investing in innovative products and services.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.